Developing the next generation of cancer therapies
Avacta is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre
CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current cancer immunotherapies as well as current high off-target toxicity experienced by most patients.
Avacta expects to enter the clinic with its lead pre
CISION™ programme, a tumour activated form of doxorubicin, in early 2021. The lead Affimer® programme, a PD-L1 Affimer® antagonist, will form the basis of future bispecifics, combinations with pre
CISION™ chemotherapies and novel tumour microenvironment activated drug conjugates (TMAC®).
Avacta has established drug development partnerships with pharma and biotech, including a research collaboration with ModernaTx, Inc., a development and commercialisation deal with LG Chem worth up to $310m and a collaboration with ADC Therapeutics to develop novel Affimer® drug conjugates. The Company is actively seeking to license its proprietary platforms in a range of therapeutic areas.
Development of high performance Affimer®-based diagnostics to improve health outcomes.
Avacta aims to become the leading provider of innovative, next generation diagnostic solutions, and the first choice for disruptive immunodiagnostic products.
Our diagnostics division is utilising our proprietary Affimer® platform to develop AffiDX®in vitro diagnostic (IVD) tests, starting with the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test.
We have also established commercial relationships with IVD companies worldwide to improve the clinical utility of diagnostic testing solutions, by combining bespoke Affimer® reagents with leading diagnostic platform technologies.
AffiDX® SARS-CoV-2 Antigen Lateral Flow Test
Affimer® technology is a novel class of biotherapeutic based on a naturally occurring human protein called Stefin A.
Avacta’s proprietary pre
CISION™ technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein (FAP?) which is highly upregulated in the tumour microenvironment of most solid tumours compared with healthy tissues.